Calprotectin — A Novel Marker of Obesity

Ole Hartvig Mortensen, Anders Rinnov Nielsen, Christian Erikstrup, Peter Plomgaard, Christian Philip Fischer, Rikke Krogh-Madsen, Birgitte Lindegaard, Anne Marie Petersen, Sarah Taudorf and Bente Klarlund Pedersen

PLOS ONE, 2009, vol. 4, issue 10, 1-4

Abstract: Background: The two inflammatory molecules, S100A8 and S100A9, form a heterodimer, calprotectin. Plasma calprotectin levels are elevated in various inflammatory disorders. We hypothesized that plasma calprotectin levels would be increased in subjects with low-grade systemic inflammation i.e. either obese subjects or subjects with type 2 diabetes. Methodology/Principal Findings: Plasma calprotectin and skeletal muscle S100A8 mRNA levels were measured in a cohort consisting of 199 subjects divided into four groups depending on presence or absence of type 2 diabetes (T2D), and presence or absence of obesity. There was a significant interaction between obesity and T2D (p = 0.012). Plasma calprotectin was increased in obese relative to non-obese controls (p

Date: 2009
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007419 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 07419&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0007419

DOI: 10.1371/journal.pone.0007419

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().